Clinical characteristics, evolution and treatment of pulmonary arterial hypertension at a Peruvian referral hospital
DOI:
https://doi.org/10.24265/horizmed.2022.v22n1.01Keywords:
Pulmonary Arterial Hypertension, Epidemiology, Therapeutics, Hospitalization, Mortality, Latin America, PeruAbstract
Objective: To describe the clinical and epidemiological characteristics, evolution and treatment of patients with pulmonary arterial hypertension.
Materials and methods: A descriptive study that included 47 patients with a primary diagnosis of pulmonary arterial hypertension. Results: The average age of the patients was 48 years and 91.49 % were females. The average follow-up was 39 months.
The main types of pulmonary arterial hypertension were the one associated with congenital heart diseases (48.93 %), the one associated with connective tissue diseases (21.28 %) and idiopathic hypertension (17.02 %). Monotherapy (mainly with sildenafil) and sequential combination therapy (sildenafil plus bosentan) were used in 78.72 % and 21.28 % of the patients,
respectively. During the follow-up, 70.21 % of the patients were hospitalized at least once and five patients died, resulting in a cumulative total mortality of 10.64 %. Conclusions: Pulmonary arterial hypertension predominantly affects young people and females. The main associated etiology is congenital heart disease. The most frequently used specific treatment is sildenafil monotherapy. The mortality rate was lower than that reported in other studies.
Downloads
References
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl): D42-50.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl): D34-41.
Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011; 139(1): 128-37.
Jiang X, Jing ZC. Epidemiology of pulmonary arterial hypertension. Curr Hypertens Rep. 2013; 15(6): 638-49.
D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5): 343-9.
Rich S, Danzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107(2): 216-23.
Zhang R, Dai L-Z, Xie W-P, Yu Z-X, Wu B-X, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011; 140(2): 301-9.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9): 1023-30.
Pittrow D, Vonk-Noordegraaf A, Vachiery J-L, Vizza CD, Huscher D, Gibbs S, et al. International, prospective registry for the documentation of first line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL): aims, design, methods, and baseline characteristics of patients. Am J Resp Crit Care Med. 2010; 181: A4806.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2): 448-56.
Alves JL, Gavilanes F, Jardim C, Fernandes CJCDS, Morinaga LTK, Dias B, et al. Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident brazilian cases. Chest. 2015; 147(2): 495-501.
Ramírez-Rivera A, Sánchez CJ, Badillo EVG, Medellín B, Rivera SR, Palacios JM, et al. Northeast mexican registry on pulmonary arterial hypertension (RENEHAP). Chest. 2010; 138(4): 372.
Villaquiran C, Duenas R, Conde R, Torres A. Description of the Clinical, Functional and Hemodynamic Characteristics of Patients with Pulmonary Arterial Hypertension in Five Reference Centers in Bogota - Colombia, at 2.640 Meters Above Sea Level. Am J Respir Crit Care Med. 2015; 191: A3842.
Zagolin BM, Wainstein GE, Uriarte GCP, Parra RC. Caracterización clínica, funcional y hemodinámica de la población con hipertensión pulmonar arterial evaluada en el Instituto Nacional del Tórax. Rev Med Chil. 2006; 134(5): 589-95.
Talavera ML, Cáneva JO, Favaloro LE, Klein F, Boughen RP, Bozovich GE, et al. Hipertensión arterial pulmonar: Registro de un centro de referencia en Argentina. Rev Am Med Respir. 2014; 14: 144-52.
Aguirre-Zurita O, Ercilla J, Sanabria S. Hipertensión arterial pulmonar en el Instituto Nacional del Corazón EsSalud. Terapia de combinación guiada por objetivos: más allá del sildenafilo. Rev Card CM Ins Nac Card. 2014; 1: 12-9.
Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174: 1034-41.
Hoeper MM, Huscher D, Pittrow D. Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol. 2016; 203: 612-3.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016; 4(4): 306-22.
Galie N, Humbert M, Vachieryc J, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016; 37: 67-119.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
